IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 39.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 994 shares of the medical research company’s stock after purchasing an additional 280 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in IQVIA were worth $210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. GAMMA Investing LLC lifted its position in IQVIA by 175.2% during the 2nd quarter. GAMMA Investing LLC now owns 809 shares of the medical research company’s stock worth $171,000 after acquiring an additional 515 shares in the last quarter. Appleton Partners Inc. MA grew its stake in IQVIA by 6.2% during the 2nd quarter. Appleton Partners Inc. MA now owns 31,603 shares of the medical research company’s stock worth $6,682,000 after buying an additional 1,854 shares during the last quarter. Cullen Investment Group LTD. increased its position in IQVIA by 2.4% in the second quarter. Cullen Investment Group LTD. now owns 19,850 shares of the medical research company’s stock worth $4,197,000 after buying an additional 458 shares during the period. Cape Investment Advisory Inc. increased its position in IQVIA by 1.1% in the first quarter. Cape Investment Advisory Inc. now owns 8,364 shares of the medical research company’s stock worth $2,115,000 after buying an additional 95 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in IQVIA by 8.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,280 shares of the medical research company’s stock worth $297,000 after buying an additional 98 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IQV. JPMorgan Chase & Co. raised their price target on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday. Truist Financial raised their price target on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Barclays raised their target price on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, Robert W. Baird raised their target price on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $265.67.

IQVIA Stock Down 3.4 %

Shares of IQV traded down $8.15 during midday trading on Monday, reaching $233.63. 1,195,182 shares of the stock were exchanged, compared to its average volume of 1,093,257. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a 50 day simple moving average of $221.77 and a 200-day simple moving average of $230.63. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market cap of $42.57 billion, a price-to-earnings ratio of 31.99, a P/E/G ratio of 2.35 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period last year, the business earned $2.22 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. Research analysts forecast that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.